Skip to content

Clinical trials

Premature Birth trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Premature Birth Phase: Not applicable Country / region: China Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20121
20151
20171
20181
20191
20205
20212
20221
20231
20242
20252
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed9
Not yet recruiting6
Unknown status6
Recruiting2
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Hospital of Fudan University7
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University4
Children's Hospital of Chongqing Medical University2
Fudan University2
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine2
Jiulongpo No.1 People's Hospital1
Nanfang Hospital, Southern Medical University1
Nanjing Medical University1
Ningbo University1
Shandong Provincial Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Premature Birth25
Respiratory Distress Syndrome3
Anemia2
Dysbiosis2
Neurodevelopmental Disorders2
Bronchopulmonary Dysplasia1
Ductus Arteriosus, Patent1
Enterocolitis, Necrotizing1
Fractures, Stress1
Hyperphagia1

Trials

Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.